Tuesday, April 26, 2016
Fibrocell Science Inc Sats receives orphan drug designation from the FDA for for FCX-013 for the treatment of localized scleroderma.
Says expect to submit an investigational new drug application for FCX-013 to fda in 2017.
Source : reuters.com
